Physician profile
Koppany Visnyei
NPI 1770897365
$287,149.27
in general payments reported to CMS, 2019-2025
51 companies · $69K in 2025
The $69K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $24K · 2021: $19K · 2022: $49K · 2023: $37K · 2024: $65K · 2025: $69K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $98K · Travel and Lodging: $33K · Consulting Fee: $24K · Food and Beverage: $17K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $97,825.00 |
| Travel and Lodging | $33,297.23 |
| Consulting Fee | $24,102.50 |
| Food and Beverage | $16,508.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $241,615.40 | 2019-2025 | Apretude, Cabenuva, Dovato |
| Gilead Sciences, INC. | $32,131.14 | 2019-2025 | Yeztugo, Descovy, Biktarvy |
| Emd Serono, INC. | $1,594.18 | 2019-2025 | Serostim |
| Biohaven Pharmaceuticals, INC. | $1,235.69 | 2020-2021 | |
| Amgen INC. | $1,190.48 | 2019-2025 | Repatha, Otezla, Repatha |
| Janssen Biotech, INC. | $1,163.69 | 2019-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $1,138.63 | 2019-2025 | Pifeltro, Delstrigo, Capvaxive |
| Napo Pharmaceuticals INC | $1,124.67 | 2019-2025 | Mytesi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $606.73 | 2019-2025 | Xifaxan |
| Bausch Health US, LLC | $558.07 | 2021-2025 | Aplenzin |
| Theratechnologies INC. | $479.20 | 2019-2024 | Trogarzo, Egrifta |
| Abbvie INC. | $477.07 | 2019-2024 | Ubrelvy, Vraylar |
| Janssen Products, Lp | $445.84 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $326.59 | 2023-2025 | Breztri, Airsupra |
| Antares Pharma, INC. | $275.61 | 2019-2024 | Xyosted, Nocdurna, Tlando |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Koppany Visnyei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.